O
OrbiMed Portfolio holdings
AUM
$3.98B
1-Year Return
13.05%
This Quarter Return
-2.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$10.7B
AUM Growth
-$753M
(-6.6%)
Cap. Flow
+$400M
Cap. Flow
% of AUM
3.75%
Top 10 Holdings %
Top 10 Hldgs %
33.33%
Holding
184
New
34
Increased
39
Reduced
24
Closed
28
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$453M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$121M |
| 3 |
Haemonetics
HAE
|
$94.6M |
| 4 |
Terns Pharmaceuticals
TERN
|
$83.4M |
| 5 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$82.9M |
Top Sells
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$319M |
| 2 |
Prelude Therapeutics
PRLD
|
$241M |
| 3 |
Pfizer
PFE
|
$133M |
| 4 |
Biogen
BIIB
|
$125M |
| 5 |
Centene
CNC
|
$120M |
Sector Composition
| 1 | Healthcare | 95.15% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Nautilus Biotechnolgy
NAUT
$82.3M
| $680K | 0.01% |
+49,375
| New | +$680K |
|
|
PPBT
152
Purple Biotech
PPBT
$2.07M
| $130K | ﹤0.01% |
1,571
-15,739
| -91% | -$1.3M |
|
153
Acadia Pharmaceuticals
ACAD
$4.3B
| – | – |
-265,772
| Closed | -$14.2M |
|
154
Acadia Healthcare
ACHC
$2.18B
| – | – |
-1,035,160
| Closed | -$52M |
|
155
Agios Pharmaceuticals
AGIO
$2.1B
| – | – |
-2,207,321
| Closed | -$95.6M |
|
156
Alcon
ALC
$39B
| – | – |
-351,380
| Closed | -$23.4M |
|
157
AtriCure
ATRC
$1.77B
| – | – |
-1,228,189
| Closed | -$68.4M |
|
158
Axsome Therapeutics
AXSM
$6.21B
| – | – |
0
| – | – |
|
|
159
Centene
CNC
$14.1B
| – | – |
-1,993,700
| Closed | -$120M |
|
160
Cogent Biosciences
COGT
$1.81B
| – | – |
-655,000
| Closed | -$7.36M |
|
161
CEL-SCI Corp
CVM
$77.4M
| – | – |
0
| – | – |
|
162
eHealth
EHTH
$121M
| – | – |
-844,046
| Closed | -$59.6M |
|
163
Eledon Pharmaceuticals
ELDN
$156M
| – | – |
-73,650
| Closed | -$1.11M |
|
164
ESSA Pharma
EPIX
$11M
| – | – |
-460,500
| Closed | -$5.49M |
|
165
4D Molecular Therapeutics
FDMT
$309M
| – | – |
-125,000
| Closed | -$5.18M |
|
166
Heron Therapeutics
HRTX
$202M
| – | – |
-1,191,846
| Closed | -$25.2M |
|
|
INZY
167
DELISTED
Inozyme Pharma
INZY
| – | – |
-400,400
| Closed | -$8.26M |
|
168
908 Devices
MASS
$198M
| – | – |
-40,000
| Closed | -$2.28M |
|
169
Outset Medical
OM
$237M
| – | – |
-8,333
| Closed | -$7.11M |
|
|
170
Pfizer
PFE
$140B
| – | – |
-3,616,600
| Closed | -$133M |
|
171
Praxis Precision Medicines
PRAX
$970M
| – | – |
-17,040
| Closed | -$14.1M |
|
172
Prothena Corp
PRTA
$442M
| – | – |
-1,797,458
| Closed | -$21.6M |
|
173
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
-1,170,900
| Closed | -$26M |
|
174
Teva Pharmaceuticals
TEVA
$21.2B
| – | – |
-1,935,200
| Closed | -$18.7M |
|
175
Viatris
VTRS
$12B
| – | – |
-535,149
| Closed | -$10M |
|